RxDoctor Payments DataLook up a doctor →

Rachel Niknam, MD

Ophthalmology · Philadelphia, PANPI 1649215245

Payments from drug & device makers

$142,259in general payments, 2019–2025

Across 403 payments — averaging $353.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$111K
  • Aerie Pharmaceuticals, Inc.$15K
  • Glaukos Corporation$11K
  • Alcon$2K
  • Sight Sciences, Inc.$629
  • Novartis$458
  • plus $3K from 20 others

What the payments were for

  • Consulting fees$18,12013%
  • Speaking & faculty fees$97,43768%
  • Travel & lodging$16,20711%
  • Food & beverage$10,4507%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$142,259 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$552,588
Medicare patients
1,081
Services billed
5,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost340$208,316
RestasisCyclosporine80$96,736
RhopressaNetarsudil Mesylate119$71,178
CombiganBrimonidine Tartrate/Timolol123$59,004
RocklatanNetarsudil Mesylat/Latanoprost51$30,420
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol96$21,081
XdemvyLotilaner11$20,818
Prednisolone Acetate341$18,318
Brinzolamide80$16,253
Alphagan PBrimonidine Tartrate44$15,275
Cyclosporine21$11,721
Latanoprost767$10,962
SimbrinzaBrinzolamide/Brimonidine Tart30$10,672
MieboPerfluorohexyloctane/Pf14$10,559
Brimonidine Tartrate144$10,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$110,602$379,331587 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$14,997$101,598170 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$347$20,81811 claims
AlconSimbrinza$1,826$10,67230 claims
Bausch & Lomb Americas Inc.Miebo$314$10,55914 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$69$5,43937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →